MYOS CORP, the sole owner and exclusive provider of FORTETROPIN, proudly announces the issuance of its 9th U.S. patent, further validating the unmatched science and proprietary nature behind its flagship ingredient, FORTETROPIN. With eight prior patents and eight compelling clinical…
MYOS CORP Secures 9th U.S. Patent, “Methods for Alleviating, Inhibiting or Reversing Muscle Disuse Atrophy in Mammals.”
This post was originally published on this site